He cited research that humans developed the CYP2D6 gene millions of years ago, and the findings suggest that humans were ...

A recent study published in Translational Psychiatry sheds new light on the diverse factors that influence how individuals ...

next examined variations in genes encoding these enzymes, including CYP2D6, across the clusters they identified with their microsatellite analysis. They found that the genetic groupings (based on ...

Concomitant strong CYP3A4 or CYP2D6 inhibitors, or CYP2D6 poor metabolizer: reduce aripiprazole dose by ½. Concomitant strong CYP3A4 inducers: double aripiprazole dose (max 30mg/day) over 1–2 ...

This article from BioIVT explores the impact of donor diversity in both phase 1 and phase 2 activities of cryopreserved human ...

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ...

Cardiovascular disease. Angle-closure glaucoma. Seizures. Psychosis. Poor metabolizers (those with reduced CYP2D6 activity). Avoid abrupt cessation. Write ℞ for smallest practical amount.

Cinacalcet is a potent inhibitor of CYP2D6. The dose of agents that are metabolized by this enzyme may need to be decreased if cinacalcet is used concomitantly. These agents include drugs for ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. You ...

Geriatrics and Aging. 2009;12(1):48-52. Transdermal fentanyl may be used for patients who do not tolerate the orally available opioids or who cannot swallow sustained-release formulations. Patches ...

Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less ...